GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Nxstage Medical, Inc. (NXTM) [hlAlert]

Rating:
Mkt Outperform
NXTM
up 26.60 %

Nxstage Medical, Inc. (NXTM) rated Mkt Outperform with price target $10 by JMP Securities

Posted on: Wednesday,  May 14, 2008  10:25 AM ET by JMP Securities

JMP Securities rated Mkt Outperform Nxstage Medical, Inc. (NASDAQ: NXTM) on 05/14/2008. Previously JMP Securities rated Buy Nxstage Medical, Inc. (NASDAQ: NXTM)
on 10/22/2007., when the stock price was $13.98. Since then, Nxstage Medical, Inc. has gained 26.61% as of 01/26/2016's recent price of $17.70.
If you would have followed the previous JMP Securities's recommendation on NXTM, you would have gained 26.6% of your investment in 3018 days.

NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/14/2008 10:25 AM Buy
None
4.81 10.00
as of 12/24/2008
1 Week down  -11.95 %
1 Month down  -2.64 %
3 Months down  -35.56 %
1 YTD down  -17.22 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/13/2008 10:25 AM Buy
None
7.87 13.00
10/22/2007 9:25 AM Buy
None
13.98 17.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy